Clinical Trials and Progress in Metastatic Colon Cancer

Surg Oncol Clin N Am. 2018 Apr;27(2):349-365. doi: 10.1016/j.soc.2017.11.008.


Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide but associated mortality has declined in recent decades. Genomic profiling of the disease has resulted in the definition of subsets of patients-for example, KRAS, NRAS, or BRAF mutated; Her2 amplified; and mismatch repair deficient-which has enabled personalization of therapeutic decision making. These subsets are guiding drug development and combination therapy approaches using both targeted therapies and immunotherapies. Further refinement based on molecular discoveries and the emergence of newer technologies to enable new discoveries allow for great optimism for the future on behalf of patients with colon cancer.

Keywords: BRAF; Clinical trials; Colorectal cancer; Her2; Immunotherapy; KRAS.

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic*
  • Colonic Neoplasms / secondary
  • Colonic Neoplasms / therapy*
  • Humans
  • Neoplasm Metastasis
  • Prognosis